Top

Published in:

Open Access 01-04-2012 | Urogenital

ESUR prostate MR guidelines 2012

Authors: Jelle O. Barentsz, Jonathan Richenberg, Richard Clements, Peter Choyke, Sadhna Verma, Geert Villeirs, Olivier Rouviere, Vibeke Logager, Jurgen J. Fütterer

Published in: European Radiology | Issue 4/2012

Abstract

The aim was to develop clinical guidelines for multi-parametric MRI of the prostate by a group of prostate MRI experts from the European Society of Urogenital Radiology (ESUR), based on literature evidence and consensus expert opinion. True evidence-based guidelines could not be formulated, but a compromise, reflected by “minimal” and “optimal” requirements has been made. The scope of these ESUR guidelines is to promulgate high quality MRI in acquisition and evaluation with the correct indications for prostate cancer across the whole of Europe and eventually outside Europe. The guidelines for the optimal technique and three protocols for “detection”, “staging” and “node and bone” are presented. The use of endorectal coil vs. pelvic phased array coil and 1.5 vs. 3 T is discussed. Clinical indications and a PI-RADS classification for structured reporting are presented.

Key Points

• This report provides guidelines for magnetic resonance imaging (MRI) in prostate cancer.

• Clinical indications, and minimal and optimal imaging acquisition protocols are provided.

• A structured reporting system (PI-RADS) is described.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef

Carter HB, Piantadosi S, Isaacs JT (1990) Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143:742–746PubMed

Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):S4–S66PubMedCrossRef

Konety BR, Bird VY, Deorah S, Dahmoush L (2005) Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 174:1785–1788, discussion 1788PubMedCrossRef

Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B et al (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59:477–494PubMedCrossRef

Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A et al (2011) Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding—multiparametric MR imaging for detection and biopsy planning. Radiology 259:162–172PubMedCrossRef

Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N et al (2010) Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 31:625–631PubMedCrossRef

Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ et al (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241:449–458PubMedCrossRef

Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S (2007) Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 25:146–152PubMedCrossRef

10.

van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA et al (2009) A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate. Eur Urol 56:981–987PubMedCrossRef

11.

Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G et al (2009) Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 103:883–888PubMedCrossRef

12.

Tamada T, Sone T, Jo Y, Toshimitsu S, Yamashita T et al (2008) Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 28:720–726PubMedCrossRef

13.

Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S et al (2011) Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 258:488–495PubMedCrossRef

14.

Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H (2011) Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 33:167–172PubMedCrossRef

15.

Hambrock T, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA et al (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259:453–461PubMedCrossRef

16.

Villeirs GM, Oosterlinck W, Vanherreweghe E, De Meerleer GO (2010) A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur J Radiol 73:352–356PubMedCrossRef

17.

Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO et al (2004) Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med 52:80–88PubMedCrossRef

18.

Girouin N, Mège-Lechevallier F, Tonina Senes A, Bissery A et al (2007) Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 17:1498–1509PubMedCrossRef

19.

Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M et al (2008) Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol 49:1207–1213PubMedCrossRef

20.

Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395PubMedCrossRef

21.

Kurhanewicz J, Vigneron D, Carroll P, Coakley F (2008) Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 18:71–77PubMedCrossRef

22.

Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23:8165–8169PubMedCrossRef

23.

Klotz L (2005) Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 47:16–21PubMedCrossRef

24.

Klotz L (2008) Active surveillance for prostate cancer: trials and tribulations. World J Urol 26:437–442PubMedCrossRef

25.

Klotz L (2008) Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it? Semin Radiat Oncol 18:2–6PubMedCrossRef

26.

Klotz LH (2005) Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol 12(Suppl 2):21–24PubMed

27.

Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M (2008) Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 101:165–169PubMed

28.

Villers A, Puech P, Mouton D, Leroy X, Ballereau C et al (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176:2432–2437PubMedCrossRef

29.

Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W (2011) Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 77:340–345PubMedCrossRef

30.

Kumar R, Nayyar R, Kumar V et al (2008) Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/mL: a follow-up study. Urology 72:859–863PubMedCrossRef

31.

Hambrock T, Somford DM, Hoeks C et al (2010) Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 183:520–527PubMedCrossRef

32.

Amsellem-Ouazana D, Younes P, Conquy S et al (2005) Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 47:582–586PubMedCrossRef

33.

Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E (2005) Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236:903–910PubMedCrossRef

34.

Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J (2012) Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 61:177–184PubMedCrossRef

35.

Panebianco V, Sciarra A, Lisi D et al (2011) Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. doi:10.1016/j.ejrad.2011.01.095

36.

Pasquier D, Hugentobler A, Masson P (2009) Which imaging methods should be used before salvage radiotherapy after prostatectomy for prostate cancer? Cancer Radiother 13:173–181PubMedCrossRef

37.

Cirillo S, Petracchini M, Scotti L et al (2009) Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 19:761–769PubMedCrossRef

38.

Haider MA, Chung P, Sweet J, Toi A, Jhaveri K et al (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70:425–430PubMedCrossRef

39.

Yakar D, Hambrock T, Huisman H, Hulsbergen-van de Kaa CA, van Lin E (2010) Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol 45:121–125PubMedCrossRef

40.

Akin O, Sala E, Moskowitz CS et al (2006) Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 239:784–792PubMedCrossRef

41.

Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H (2008) Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology 246:168–176PubMedCrossRef

42.

Oto A, Kayhan A, Jiang Y et al (2010) Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 257:715–723PubMedCrossRef

43.

Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 23:65–83PubMedCrossRef

44.

Huisman HJ, Engelbrecht MR, Barentsz JO (2001) Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging 13:607–614PubMedCrossRef

45.

Alonzi R, Padhani AR, Allen C (2007) Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 63:335–350PubMedCrossRef

46.

Barentsz JO, Engelbrecht M, Jager GJ et al (1999) Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10:295–304PubMedCrossRef

47.

Engelbrecht MR, Huisman HJ, Laheij RJ et al (2003) Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 229:248–254PubMedCrossRef

48.

Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V (2005) Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62:140–147PubMedCrossRef

49.

Beyersdorff D, Taupitz M, Winkelmann B et al (2002) Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 224:701–706PubMedCrossRef

50.

Haider MA, van der Kwast TH, Tanguay J et al (2007) Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 189:323–328PubMedCrossRef

51.

Kim CK, Park BK, Lee HM, Kwon GY (2007) Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 42:842–847PubMedCrossRef

52.

Lim HK, Kim JK, Kim KA, Cho KS (2009) Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection—a multireader study. Radiology 250:145–151PubMedCrossRef

53.

Testa C, Schiavina R, Lodi R et al (2007) Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11 C-choline PET/CT. Radiology 244:797–806PubMedCrossRef

54.

Jung JA, Coakley FV, Vigneron DB et al (2004) Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 233:701–708PubMedCrossRef

55.

Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 198:795–805PubMed

56.

Sciarra A, Panebianco V, Ciccariello M et al (2010) Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest 28:424–432PubMed

57.

Futterer JJ, Scheenen TW, Heijmink SW et al (2007) Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 42:116–122PubMedCrossRef

58.

Yuen JS, Thng CH, Tan PH et al (2004) Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171:1482–1486PubMedCrossRef

59.

Sciarra A, Panebianco V, Salciccia S et al (2008) Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 54:589–600PubMedCrossRef

60.

Zakian KL, Hricak H, Ishill N et al (2010) An exploratory study of endorectal magnetic resonance imaging and spectroscopy of the prostate as preoperative predictive biomarkers of biochemical relapse after radical prostatectomy. J Urol 184:2320–2327PubMedCrossRef

61.

De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM (2010) Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 194:1427–1433PubMedCrossRef

62.

Rouviere O, Vitry T, Lyonnet D (2010) Imaging of prostate cancer local recurrences: why and how? Eur Radiol 20:1254–1266PubMedCrossRef

63.

Shukla-Dave A, Hricak H, Ishill N et al (2009) Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res 15:3842–3849PubMedCrossRef

64.

Pucar D, Shukla-Dave A, Hricak H et al (2005) Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 236:545–553PubMedCrossRef

65.

Coakley FV, Teh HS, Qayyum A et al (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448PubMedCrossRef

66.

Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M III (2004) Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60:1047–1055PubMedCrossRef

67.

Kim CK, Park BK, Kim B (2010) Diffusion-weighted MRI at 3T for the evaluation of prostate cancer. AJR Am J Roentgenol 194:1461–1469PubMedCrossRef

68.

BottomLey PA, Foster TH, Argersinger RE, Pfeifer LM (1984) A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 11:425–448PubMedCrossRef

69.

Ahmed HU, Kirkham A, Arya M et al (2009) Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 6:197–206PubMedCrossRef

70.

Cornfeld DM, Weinreb JC (2007) MR imaging of the prostate: 1.5 T versus 3 T. Magn Reson Imaging Clin N Am 15:433–448, viiiPubMedCrossRef

71.

Leautaud A, Marcus C, Ben SD, Bouche O, Graesslin O, Hoeffel C (2009) Pelvic MRI at 3.0 Tesla. J Radiol 90(3 Pt 1):277–286PubMedCrossRef

72.

Mueller-Lisse U, Scheidler J, Klein G, Reiser M (2005) Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists. Eur Radiol 15:1826–1833PubMedCrossRef

73.

Nogueira L, Wang L, Fine SW et al (2010) Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 75:472–477PubMedCrossRef

74.

Arumainayagam N, Kumaar S, Ahmed HU et al (2010) Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 106:991–997PubMedCrossRef

75.

Jung JA, Coakley FV, Vigneron DB et al (2004) Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 233:701–708PubMedCrossRef

76.

Villers A, Lemaitre L, Haffner J, Puech P (2009) Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol 19:274–282PubMedCrossRef

Title: ESUR prostate MR guidelines 2012
Authors: Jelle O. Barentsz
Jonathan Richenberg
Richard Clements
Peter Choyke
Sadhna Verma
Geert Villeirs
Olivier Rouviere
Vibeke Logager
Jurgen J. Fütterer
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: European Radiology / Issue 4/2012
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-011-2377-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

ESUR prostate MR guidelines 2012

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival

Increase in perceived case suspiciousness due to local contrast optimisation in digital screening mammography

Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation

The added value of quantitative multi-voxel MR spectroscopy in breast magnetic resonance imaging

Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases

Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study